OOIR: Observatory of International Research

Papers

(The TQCC of npj Precision Oncology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Patient-derived organoids as a predictive biomarker for treatment response in cancer patients	140
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population	96
High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients	71
Blood-derived lncRNAs as biomarkers for cancer diagnosis: the Good, the Bad and the Beauty	66
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma	64
Microbiome dysbiosis in lung cancer: from composition to therapy	64
Quantitative MRI-based radiomics for noninvasively predicting molecular subtypes and survival in glioma patients	61
Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance	61
Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity	60
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy	56
The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response	50
GD2 CAR T cells against human glioblastoma	50
Genetic mutation and biological pathway prediction based on whole slide images in breast carcinoma using deep learning	47
Will polygenic risk scores for cancer ever be clinically useful?	43
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors	42
Survival improvement for patients with metastatic colorectal cancer over twenty years	40
Clinical application of a lung cancer organoid (tumoroid) culture system	40
Antibody-drug conjugates in lung cancer: dawn of a new era?	40
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes	38
Structural variant detection in cancer genomes: computational challenges and perspectives for precision oncology	38
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer	37
Identification of gastric cancer subtypes based on pathway clustering	36
Deep learning for end-to-end kidney cancer diagnosis on multi-phase abdominal computed tomography	35
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib	34
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance	34

High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition	33
Targeting CDK1 in cancer: mechanisms and implications	33
A phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors	33
Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)	33
Dynamic roles of inflammasomes in inflammatory tumor microenvironment	33
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients	32
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer	32
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance	31
Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer	30
Just Add Data: automated predictive modeling for knowledge discovery and feature selection	29
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer	29
Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images	29
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma	29
Self-supervised attention-based deep learning for pan-cancer mutation prediction from histopathology	29
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas	28
Plasma cell-free RNA profiling distinguishes cancers from pre-malignant conditions in solid and hematologic malignancies	27
Co-occurring genomic alterations and immunotherapy efficacy in NSCLC	27
Cell graph neural networks enable the precise prediction of patient survival in gastric cancer	27
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy	27
Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review	26
Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA	26
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes	26
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy	25
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient	25
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome	24
Single-cell spatial architectures associated with clinical outcome in head and neck squamous cell carcinoma	24
Prostate cancer polygenic risk score and prediction of lethal prostate cancer	24
Splice-switching of the insulin receptor pre-mRNA alleviates tumorigenic hallmarks in rhabdomyosarcoma	24
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients	24
Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury	23
Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis	23
Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients	23
Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade	22
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer	22
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets	21
Usability of deep learning and H&E images predict disease outcome-emerging tool to optimize clinical trials	20
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer	20
Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features	20
A deep learning model for molecular label transfer that enables cancer cell identification from histopathology images	20
Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells	20
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition	20
Spatially variant immune infiltration scoring in human cancer tissues	19
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis	19
Efficacy of MEK inhibition in a recurrent malignant peripheral nerve sheath tumor	19
Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia	19
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors	19
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer	19
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics	19
Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade	19
Deep learning generates synthetic cancer histology for explainability and education	19

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma	19
Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns	19
Genomic landscape of 891 RET fusions detected across diverse solid tumor types	18
Artificial intelligence in ovarian cancer histopathology: a systematic review	18
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?	18
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	18
Imaging immunity in patients with cancer using positron emission tomography	18
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial	18
Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types	17
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations	17
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	17
Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance	17
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors	17
Precision medicine: affording the successes of science	17
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma	17
Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups	17
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features	16
Artificial intelligence for the next generation of precision oncology	16
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia	16
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer	16
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations	16
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions	16
Rare deleterious germline variants and risk of lung cancer	16
The Aurora kinase/β-catenin axis contributes to dexamethasone resistance in leukemia	16
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures	16
Impact of TP53 mutations in Triple Negative Breast Cancer	15
Acetylation of ELF5 suppresses breast cancer progression by promoting its degradation and targeting CCND1	15
Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target	15
Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma	15
On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer	15
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial	15
MatchMiner: an open-source platform for cancer precision medicine	15
Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case	15
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM	15
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer	15
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis	15
Racial and ethnic disparities in a real-world precision oncology data registry	15
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer	15
Circulating stromal cells in resectable pancreatic cancer correlates to pathological stage and predicts for poor clinical outcomes	14
Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification	14
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies	14
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology	14
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia	14
First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound	14
Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment	14
Tumor-associated macrophage-related strategies for glioma immunotherapy	13
Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration	13
Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients	13
Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression	13
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy	13
Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study	13
Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer	13
ALK fusions in the pan-cancer setting: another tumor-agnostic target?	13
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer	13
Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors	13
Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer	13
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study	13
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations	13
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing	13
Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium	13
Characterization of evolution trajectory and immune profiling of brain metastasis in lung adenocarcinoma	13
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma	12
Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition	12
Prediction of early-stage melanoma recurrence using clinical and histopathologic features	12
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer	12
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy	12
Profiling the heterogeneity of colorectal cancer consensus molecular subtypes using spatial transcriptomics	12
Advances in NK cell therapy for brain tumors	12
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality	12
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer	12
Patient-level proteomic network prediction by explainable artificial intelligence	12
Radiomics for characterization of the glioma immune microenvironment	12
Epigenomics and immunotherapeutic advances in pediatric brain tumors	12
Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma	12
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity	12
A DNA methylation-based liquid biopsy for triple-negative breast cancer	12
DNA-based copy number analysis confirms genomic evolution of PDX models	12